Разработка системы продукции лактоферрина человека in ovo и in vivo с использованием рекомбинантных аденовирусов

Список литературы

1. Канышкова Т.Г., Бунева В. Н., Невинский Г. А. Лактоферрин и его биологические функции //Биохимия. 2001. — Том 66. — вып. 1. — С. 5−13.
2. Маниатис Т., Фрич Э., Сэмбрук Дж. Молекулярное клонирование. -М.:Мир, 1982.
3. Немцова Е.Р., Сергеева Т. В., Безбородова О. А., Якубовская Р. И. Антиоксиданты — место и роль в онкологии // Российский онкологический журнал. 2003. — № 5. — С. 48−53.
4. Немцова Е. Р., Эделева Н. В., Осипова Н. А., Якубовская Р. П., Бойко А. В., Демидова Л. В., Чиссов В. И. Детоксицирующее, противовоспалительное и иммуномодулирующее действие лапрота // Российский онкологический журнал. 2006. — № 4. — С. 29−33.
5. Фомина Н.В. Аденовирусная инфекция животных. М.: Колос, 1995.
6. Эделева Н.В., Осипова Н. А., Якубовская Р. И. Новые возможности профилактики и коррекции послеоперационных гнойно-септических осложнений и полиорганной недостаточности в онкохирургии// Анестезиология и реаниматология.-1997, № 3, С.36−41.
7. Якубовская Р.И., Немцова Е. Р., Коростелева М. Д. К методике синтезааффинных сорбентов // Лабораторное дело. — 1987. № 7, С. 536−539.
8. Якубовская Р.И., Немцова Е. Р., Сургай В. В. Коррекция гомеостаза у онкологических больных препаратом Лапрот// Российский онкологический журнал.- 1996, № 2.- С.10−13
9. Afeltra A., Caccavo D., Ferri G. M., Adessi M. A., De Rosa F. G., Amoroso A. et al. Expression of lactoferrin on human granulocytes: analysis with polyclonal and monoclonal antibodies. // Clin. Exp. Immunol. 1997. — V. 109. — P. 279 285.
10. Akopian T.A., Doronin K.K., Karpov V.A., Naroditsky B.S. Sequence of the avian adenovirus FAV-1 (CELO) DNA encoding the hexon-associated protein pVI and hexon. //Arch.Virol. 1996. — V. 141. — P. 1759−1765.
11. Anderson J., V.J. Yates, et al. The in vitro transformation by an avian adenovirus (CELO). I. Hamster-embryo fibroblastic cultures. J. Natl. Cancer Inst. 1969. V. 42.-P. 1−7.
12. Anderson J, Yates VJ, Jasty V, Mancini LO. In vitro transformation by an avian adenovirus (CELO). II. Hamster kidney cell cultures. // J Natl Cancer Inst. — 1969.-V. 43.-P. 65−70.
13. Anderson BF, Baker HM, Norris GE, Rice DW, Baker EN. Structure of human lactoferrin: crystallographic structure analysis and refinement at 2.8 A resolution. // J. Mol. Biol. 1989. — V. 209.-P. 711−734.
14. Anderson C.W., Young M.E., Flint S.J. Characterization of the adenovirus 2 virion protein, mu. // Virology.-1989. -V. 172. P. 506−512.
15. Anderson BF, Baker HM, Norris GE, Rumball SV, Baker EN. Apolactoferrin structure demonstrates ligand-induced conformational change in transferrins.// Nature. 1990. — V. 344. — P. 784−787.
16. Appelmelk В J, An YQ, Geerts M, Thijs BG, de Boer HA, MacLaren DM, de Graaff J, Nuijens JH. Lactoferrin is a lipid A-binding protein. // Infect Immun. — 1994. V. 62. — P. 2628−2632.
17. Arnold RR, Cole MF, McGhee JR. A bactericidal effect for human lactoferrin. // Science. 1977. — V. 97. — P. 263−265.
18. Arnold SB, Byrd RC, Meister W, Melmon K, Cheitlin MD, Bristow JD, Parmley WW, Chatterjee K. Long-term digitalis therapy improves left ventricular function in heart failure. // N Engl J Med. 1980. — V. 303. — P. 1443−1448.
19. Ashida K, Sasaki H, Suzuki YA, Lonnerdal B. Cellular internalization of lactoferrin in intestinal epithelial cells. // Biometals. — 2004. V. 17. — P. 311 315.
20. Barnett BG, Crews CJ, Douglas JT. Targeted adenoviral vectors. // Biochim Biophys Acta. 2002. — V. 1575. — P. 1−14.
21. Bauerschmitz GJ, Lam JT, Kanerva A, Suzuki K, Nettelbeck DM, Dmitriev I, Krasnykh V, Mikheeva GV, Barnes MN, Alvarez RD, Dall P, Alemany R,
22. Curiel DT, Hemminki A. Treatment of ovarian cancer with a tropism modified oncolytic adenovirus. // Cancer Res. 2002. — V. 62. — P. 1266−1270.
23. Bellamy W, Takase M, Yamauchi K, Wakabayashi H, Kawase K, Tomita M. Identification of the bactericidal domain of lactoferrin. // Biochim Biophys Acta. 1992. — V. 1121.-P. 130−136.
24. Bennett RM, Kokocinski T. Lactoferrin content of peripheral blood cells. // Br J Haematol. 1978,-V. 39. — P.509−521.
25. Bennett RM, Davis J. Lactoferrin interacts with deoxyribonucleic acid: a preferential reactivity with double-stranded DNA and dissociation of DNA-anti-DNA complexes. // J Lab Clin Med. 1982. — V. 99. — P. 127−138.
26. Berger J, Hauber J, Hauber R, Geiger R, Cullen BR Secreted placental alkaline phosphatase: a powerful new quantitative indicator of gene expression in eukaryotic cells.// Gene. 1988. V.66. — P. 1−10.
27. Bett AJ, Haddara W, Prevec L, Graham FL. An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3. // Proc Natl Acad Sci USA.- 1994. V. 91. — P. 8802−8806.
28. Bischoff JR, Kirn DH, Williams A, Heise C, Horn S, Muna M, Ng L, Nye JA, Sampson-Johannes A, Fattaey A, McCormick F. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. // Science. — 1996. — V. 274.-P. 373−376.
29. Bouri K, Feero WG, Myerburg MM, Wickham TJ, Kovesdi I, Hoffman EP, Clemens PR. Polylysine modification of adenoviral fiber protein enhances muscle cell transduction. // Hum Gene Ther. 1999. — V. 10. — P. 1633−1640.
30. Brandenburg К, Jiirgens G, Muller M, Fukuoka S, Koch MH. Biophysical characterization of lipopolysaccharide and lipid A inactivation by lactoferrin. // Biol Chem. 2001. -V. 382.- P. 1215−1225.
31. Britigan BE, Lewis TS, Waldschmidt M, McCormick ML, Krieg AM. Lactoferrin binds CpG-containing oligonucleotides and inhibits their immunostimulatory effects on human В cells. // J Immunol. — 2001. V. 167. -P. 2921−2928.
32. Bruder JT, Jie T, McVey DL, Kovesdi I. Expression of gpl9K increases the persistence of transgene expression from an adenovirus vector in the mouse lung and liver. // J. Virol. 1997. — V. 71. — P. 7623−7628.
33. Buchschacher GL Jr, Wong-Staal F. Development of lentiviral vectors for gene therapy for human diseases. // Blood. 2000. — V. 95. — P. 2499−2504.
34. Bullen JJ. Iron-binding proteins in milk and resistance to Escherichia coli infection in infants. // Proc R Soc Med. 1972. — V. 65. — P. 1086.
35. Bullen JJ, Rogers HJ, Griffiths E. Role of iron in bacterial infection. // Curr Top Microbiol Immunol. 1978. — V. 80. — P. 1−35.
36. Caccavo D, Sebastiani GD, Di Monaco C, Guido F, Galeazzi M, Ferri GM, Bonomo L, Afeltra A. Increased levels of lactoferrin in synovial fluid but not in serum from patients with rheumatoid arthritis. // Int J Clin Lab Res. — 1999. — V. 29. P. 30−35.
37. Caccavo D, Pellegrino NM, Altamura M, Rigon A, Amati L, Amoroso A, Jirillo E. Antimicrobial and immunoregulatory functions of lactoferrin and its potential therapeutic application. // J Endotoxin Res. 2002. — V. 8. — P. 403−417.
38. Chen CY, Bessesen DH, Jackson SM, Hoeffler JP. Overexpression and purification of transcriptionally competent CREB from a recombinant baculovirus.// Protein .Expr Purif. 1991. — V. 2. — P. 402−411.
39. Chen HH, Mack LM, Kelly R, Ontell M, Kochanek S, Clemens PR. Persistence in muscle of an adenoviral vector that lacks all viral genes. // Proc. Natl. Acad. Sci. USA 1997. V. 94.-P. 1645−1650
40. Chiocca S., Kurzbauer R., Schaffner J., Baker A., Maunter V., Cotten M. The complete DNA sequence and genomic organization of the avian adenovirus CELO. // J. Virol. 1996. — V. 70. — P. 2939−2949.
41. Chiocca, S., A. Baker, and M. Cotten. Identification of a novel antiapoptotic protein, GAM-1, encoded by the CELO adenovirus. // J. Virol. 1997. — V. 71. -P. 3168−3177.
42. Choi SM, Lee OS, Kwon SY, Kwak SS, Yu DY, Lee HS. High expression of a human lactoferrin in transgenic tobacco cell cultures.// Biotechnol. Lett. — 2003. -V. 25.-P. 213−218.
43. Chu G, Hayakawa H, Berg P. Electroporation for the efficient transfection of mammalian cells with DNA. // Nucleic Acids Res. 1987. — V. 15. — P. 13 111 326.
44. Cohen P. The role of protein phosphorylation in the hormonal control of enzyme activity. // Eur. J. Biochem. 1985. — Y. 151. — P. 439−448.
45. Cotten M, Wagner E, Zatloukal K, Birnstiel ML. Chicken adenovirus (CELO virus) particles augment receptor-mediated DNA delivery to mammalian cells and yield exceptional levels of stable transformants. // J. Virol. 1993. — Y.67. -P. 3777−3785.
46. Cowen B, Calnek BW, Menendez NA, Ball RF./ Avian adenoviruses: effect on egg production, shell quality, and feed consumption. // Avian Dis. 1978. — V. 22. — P. 459−470.
47. Cuesta R, Xi Q, Schneider RJ. Structural basis for competitive inhibition of eIF4G-Mnkl interaction by the adenovirus 100-kilodalton protein. // J. Virol. -2004. V. 78. — P. 7707−7716.
48. Culver KW, Blaese RM. Gene therapy for cancer. // Trends Genet. — 1994. V. 10.-P. 174−178.
49. Curiel DT, Agarwal S,' Wagner E, Cotten M. Adenovirus enhancement of transferrin-polylysine-mediated gene delivery. // Proc. Natl. Acad. Sci. US A.-1991.-V. 88.-P. 8850−8854.
50. Curiel DT. High-efficiency gene transfer employing adenovirus-polylysine-DNA complexes. // Nat. Immun. 1994. — V. 13. — P. 141−164.
51. Davison A J, Benko M, Harrach B. Genetic content and evolution of adenoviruses. // J Gen Virol. 2003. — V. 84. — P. 2895−2908.
52. Deriy LV, Chor J, Thomas LL. Surface expression of lactoferrin by resting neutrophils. // Biochem Biophys Res Commun. 2000. — V. 275. — P. 241−246.
53. Deryckere F, Burgert HG. Early region 3 of adenovirus type 19 (subgroup D) encodes an HLA-binding protein distinct from that of subgroups В and C. // J Virol. 1996. — V. 70. — P. 2832−2841.
54. Dial EJ, Dohrman AJ, Romero JJ, Lichtenberger LM. Recombinant human lactoferrin prevents NSAID-induced intestinal bleeding in rodents. // J Pharm Pharmacol. 2005. — V. 57. — P. 93−99.
55. Doronin K, Kuppuswamy M, Toth K, Tollefson AE, Krajcsi P, Krougliak V, Wold WS. Tissue-specific, tumor-selective, replication-competent adenovirus vector for cancer gene therapy. //J Virol. 2001. — V. 75. — P. 3314−3324.
56. Douglas JT. Adenoviral vectors for gene therapy.// Mol. Biotechnol. 2007. -V. 36.-P. 71−80.
57. Elass-Rochard E, Legrand D, Salmon V, Roseanu A, Trif M, Tobias PS, Mazurier J, Spik G. Lactoferrin inhibits the endotoxin interaction with CD 14 by competition with the lipopolysaccharide-binding protein. // Infect. Immun. — 1998.-V. 66.-P. 486−491.
58. Ellison R. T. 3rd, Giehl T. J. and LaForce F. M. Damage of the outer membrane of enteric gram-negative bacteria by lactoferrin and transferrin. // Infect. Immun.- 1988. V. 56. — P. 2774−2781
59. Engelhardt JF, Litzky L, Wilson JM. Prolonged transgene expression in cotton rat lung with recombinant adenoviruses defective in E2a. // Hum Gene Ther. — 1994.- V. 5.-P. 1217−1229.
60. Fallaux F et al./ Characterization of 911, a new helper cell line for the titration and propagation of early region 1-deleted adenoviral vectors.// Hum Gene Ther. 1996. — V.7.- P. 215−222.
61. Feigner PL. Improvements in cationic liposomes for in vivo gene transfer. 11 Hum Gene Ther. 1996.-V. 7.-P. 1791−1793.
62. Ferrari F.K., Samulski Т., Shenk Т., Samulski R.J. Second-strand synthesis is a rate-limiting step for efficient transduction by recombinant adeno-associated virus vectors. // J.Virol. 1996. — V. 70. — P. 3227−3234.
63. Flotte TR, Carter BJ. Adeno-associated virus vectors for gene therapy. // Gene Ther. 1995. — V. 2. — P. 357−362.
64. Francois A, Eterradossi N, Delmas B, Payet V, Langlois P.// Construction of avian adenovirus CELO recombinants in cosmids. J.Virol. 2001. — V. 75. — P. 5288−5301.
65. Francois, A., Chevalier, C., Delmas, B. et al. // Vaccine. 2004. — V. 2. — P. 2351−2360.
66. Fransson GB, Lonnerdal B. Iron in human milk. // J Pediatr. 1980. — V. 96. — P. 380−384.
67. Freund CT, Tong XW, Block A, Contant CF, Kieback DG, Rowley DR, Lerner SP. Adenovirus-mediated suicide gene therapy for bladder cancer: comparison of the cytomegalovirus- and Rous sarcoma virus-promoter. // Anticancer Res. -2000.-V. 20.-P. 2811−2816.
68. Fujihara T, Hayashi K. Lactoferrin inhibits herpes simplex virus type-1 (HSV-1) infection to mouse cornea. // Arch Virol. 1995. — V. 140. — P. 1469−1472.
69. Fujiyama К, Sakai Y, Misaki R, Yanagihara I, Honda T, Anzai H, Seki T. N-linked glycan structures of human lactoferrin produced by transgenic rice. // Biosci Biotechnol Biochem. 2004. — V. 68. — P. 2565−2570.
70. Furmanski P, Li ZP, Fortuna MB, Swamy CV, Das MR. Multiple molecular forms of human lactoferrin. Identification of a class of lactoferrins that possess ribonuclease activity and lack iron-binding capacity. // J Exp Med. 1989. — V. 170.-P. 415−429.
71. Gall J, Kass-Eisler A, Leinwand L, Falck-Pedersen E. Adenovirus type 5 and 7 capsid chimera: fiber replacement alters receptor tropism without affecting primary immune neutralization epitopes. // J. Virol. — 1996. V. 70. — P. 21 162 123.
72. Gao GP, Yang Y, Wilson JM. Biology of adenovirus vectors with El and E4 deletions for liver-directed gene therapy. // J. Virol. 1996. — V. 70. — P. 89 348 943.
73. Glasgow JN, Everts M, Curiel DT. Transductional targeting of adenovirus vectors for gene therapy. // Cancer Gene Ther. 2006. — V. 13. — P. 830−844.
74. Glotzer JB, Saltik M, Chiocca S, Michou AI, Moseley P, Cotten M. Activation of heat-shock response by an adenovirus is essential for virus replication. // Nature. 2000. — V. 407. — P. 207−211.
75. Gomez HF, Ochoa TJ, Carlin LG, Cleary TG. Human lactoferrin impairs virulence of Shigella flexneri. // J Infect Dis. 2003. — V. 187, N 1. — P. 87−95.
76. Gordon D., Davis J., Fox P., Malech H., Gallin J., Baraniuk J. et al. Glandular secretion of lactoferrin in a patient with neutrophil lactoferrin defi ciency. // J. Allergy Clin. Immunol. 1989. -V. 84. — P. 914−919.
77. Gorziglia M et at./ Generation of an adenovirus vector lacking 11, B2a, E3, and all of E4 except open reading frame 3.// J. Virol. 1999. — V. 73. — P. 6048−6055.
78. Graham FL, Smiley J, Russel WC, Nairn R./ Characteristics of a human cell line transformed by DNA from human adenovirus type 5.11 J. Gen. Virol. — 1977. -V. 36. P. 59−74.
79. Graham F.L. and van der Eb A., J. A new technique for the assay of infectivity of human adenovirus 5 DNA.// Virology. 1973. — V. 52. — P. 456−467.
80. Graham F.L., and Prevec L. Manipulation of adenovirus vectors. // Methods in Mol. Biol. 1991.-V. 7.-P. 109−127.
81. Green K.Y., Wold W.S.M. Human adenoviruses: growth, purification and transfection assay.// Methods Enzymology. 1980. — V. 80. — P. 425−431.
82. Guillen C, Mclnnes IB, Vaughan DM, Kommajosyula S, Van Berkel PH, Leung BP, Aguila A, Brock JH. Enhanced Thl response to Staphylococcus aureus infection in human lactoferrin-transgenic mice. // J Immunol. 2002. — V. 168. -P. 3950−3957.
83. Han ZS, Li QW, Zhang ZY, Xiao B, Gao DW, Wu SY, Li J, Zhao HW, Jiang ZL, Hu JH. High-level expression of human lactoferrin in the milk of goats byusing replication-defective adenoviral vectors. // Protein Expr Purif. 2007. — V. 53.-P. 225−231.
84. Han ZS, Li QW, Zhang ZY, Yu YS, Xiao B, Wu SY, Jiang ZL, Zhao HW, Zhao R, Li J. Adenoviral vector mediates high expression levels of human lactoferrin in the milk of rabbits. //J. Microbiol. Biotechnol. -2008. V. 18. — P. 153−159.
85. Hanahan D. Studies of transformation of Escherichia coli with plasmids. // J. Mol. Biol. 1983. — V. 166. — P. 557−580.
86. Haversen L, Ohlsson BG, Hahn-Zoric M, Hanson LA, Mattsby-Baltzer I. Lactoferrin down-regulates the LPS-induced cytokine production in monocytic cells via NF-kappa B. // Cell Immunol. 2002. — V. 220. — P. 83−95.
87. Hawkins LK, Lemoine NR, Kim D. Oncolytic biotherapy: a novel therapeutic plafform. // Lancet Oncol. 2002. — V. 3. — P. 17−26.
88. Hendrixson DR, Qiu J, Shewry SC, Fink DL, Petty S, Baker EN, Plaut AG, St Geme JW 3rd. Human milk lactoferrin is a serine protease that cleaves Haemophilus surface proteins at arginine-rich sites. // Mol Microbiol. — 2003. — V. 47.-P. 607−617.
89. Hess, M., A. Cuzange, R. W. H. Ruigrok, J. Chroboczek, and B. Jacrot./ The avian adenovirus penton: two fibres and one base.// J. Mol. Biol. 1995. — V. 252. — P. 379−385.
90. Hodgson CP. The vector void in gene therapy. 11 Biotechnology (N Y). 1995. -V. 13.-P. 222−225.
91. Holmes D., Quigley M. A rapid boiling method for the preparation of bacterial plasmids. // Anal. Biochem. 1981. — V. 114. — P. 193−197.
92. Horiguchi Y, Larchian WA, Kaplinsky R, Fair WR, Heston WD. Intravesical liposome-mediated interleukin-2 gene therapy in orthotopic murine bladder cancer model. // Gene Ther. 2000. — V. 7. — P. 844−851.
93. Huang, W., Flint, SJ. The tripartite leader sequence of subgroup С adenovirus major late mRNAs can increase the efficiency of mRNA export. // J. Virol. -1998.-V.72.-P. 225−235.
94. Hwang SA, Kruzel ML, Actor JK. Lactoferrin augments BCG vaccine efficacy to generate T helper response and subsequent protection against challenge with virulent Mycobacterium tuberculosis. // Int Immunopharmacol. 2005. — V. 5. -P. 591−599.
95. Ishikado A, Imanaka H, Kotani M, Fujita A, Mitsuishi Y, Kanemitsu T, Tamura Y, Makino T. Liposomal lactoferrin induced significant increase of the interferon-alpha (IFN-alpha) producibility in healthy volunteers. // Biofactors. -2004.-V. 21.-P. 69−72.
96. Ju DW, WANG BM, Cao X. Adenovirus-mediated combined suicide gene and interleukin-2 gene therapy for the treatment of established tumor and induction of antitumor immunity. // J Cancer Res Clin Oncol. 1998. V. 124. P. 683−689.
97. Kane SV, Sandborn WJ, Rufo PA, Zholudev A, Boone J, Lyerly D, Camilleri M, Hanauer SB. Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation. // Am J Gastroenterol. 2003. — V. 98. — P. 1309−1314.
98. Kaplan JM, Armentano D, Scaria A, Woodworth LA, Pennington SE, Wadsworth SC, Smith AE, Gregory RJ. Novel role for E4 region genes in protection of adenovirus vectors from lysis by cytotoxic T lymphocytes. // J. Virol. 1999. — V. 73. — P. 4489−4492.
99. Kawaguchi T, Nomura K, Hirayama Y, Kitagawa T. Establishment and characterization of a chicken hepatocellular carcinoma cell line, LMH. // Cancer Res. 1987. — V. 47. — P. 4460−4464.
100. Kay MA, Li Q, Liu TJ, Leland F, Toman C, Finegold M, Woo SL. Hepatic gene therapy: persistent expression of human alpha 1-antitrypsin in mice after direct gene delivery in vivo. II Hum Gene Ther. 1992. — V. 3. — P. 641−647.
101. Kim SJ, Yu DY, Рак KW, Jeong S, Kim SW, Lee KK. Structure of the human lactoferrin gene and its chromosomal localization. // Mol Cells. — 1998. — V. 8. — P. 663−668.
102. Kochanek S, Schiedner G, Volpers C. High-capacity 'gutless' adenoviral vectors. // Curr Opin Mol Ther. 2001. — V. 3. — P. 454−463.
103. Krasnykh VN, Mikheeva GV, Douglas JT, Curiel DT. Generation of recombinant adenovirus vectors with modified fibers for altering viral tropism. // J. Virol. 1996. — V. 70. — P. 6839−6846.
104. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. // Nature. 1970. — V. 227. — P. 680−685.
105. Larsen A, Hovdenak N, Karlsdottir A, Wentzel-Larsen T, Dahl O, Fagerhol MK. Faecal calprotectin and lactoferrin as markers of acute radiation proctitis: a pilot study of eight stool markers. // Scand J Gastroenterol. 2004. — V. 39. — P. 11 131 118.
106. Laver WG, Younghusband HB, Wrigley NG/ Purification and properties of chick embryo lethal orphan virus (an avian adenovirus).// Virology. — 1971. V. 45. — P. 598−614.
107. Le Goff F, Mederle-Mangeot I, Jestin A, Langlois P. Deletion of open reading frames 9, 10 and 11 from the avian adenovirus CELO genome: effect on biodistribution and humoral responses. // J Gen Virol. 2005. — V. 86. — P. 2019−2027.
108. Lee RJ, Low PS. Delivery of liposomes into cultured KB cells via folate receptor-mediated endocytosis. // J Biol Chem. 1994. — V. 269. — P. 31 983 204.
109. Lee WJ, Farmer JL, Hilty M, Kim YB. The protective effects of lactoferrin feeding against endotoxin lethal shock in germfree piglets. // Infect Immun. — 1998.-V. 66. -P.1421−1426.
110. Lee Y. В., Glover C. P., Cosgrave A. S. Bienemann A, Uney J. B. Optimizing regulatable gene expression using adenoviral vectors.// Uney. J.B. Exp. Physiol. -2005-V.90.-P. 33−37.
111. Legerski R., Robberson D. Analysis and optimization of recombinant DNA joining reactions. I I Journal of Molecular Biology. 1985. — V. 181. — P. 297 312.
112. Legrand D, Salmon V, Coddeville B, Benaissa M, Plancke Y, Spik G. Structural determination of two N-linked glycans isolated from recombinant human lactoferrin expressed in BHK cells. // FEBS Lett. 1995. — V. 365. — P. 57−60.
113. Legrand D, Elass E, Pierce A, Mazurier J. Lactoferrin and host defence: an overview of its immuno-modulating and anti-inflammatory properties. // Biometals. 2004. — V. 17. — P. 225−229.
114. Lehrmann, H., and M. Cotten. Characterization of CELO virus proteins that modulate the pRb/E2 °F pathway. // J Virol. 1999. — V. 73. — P.6517−6525.
115. Leppard K.N. E4 gene function in adenovirus, adenovirus vector and adeno-associated virus infections. // J. Gen. Virology. 1997. — V. 78. — P. 2131−2138.
116. Levay PF, Viljoen M. Lactoferrin: a general review. // Haematologica. 1995. -V. 80.-P. 252−267.
117. Leveugle B, Mazurier J, Legrand D, Mazurier C, Montreuil J, Spik G. Lactotransferrin binding to its platelet receptor inhibits platelet aggregation. // Eur J Biochem. 1993, — V. 213.-P. 1205−1211.
118. Li P. et al./ The structural proteins of chick embrio lethal orphan virus (FAV-1).// J.Gen.Virol. 1984. — V. 65. — P. 1803−1815.
119. Li Z.L., Tian P. X., Xue W.J.et al Co-expression of sCD40LIg and CTLA4Ig mediated by adenovirus prolonged mouse skin allograft survival. // Univ. Sci. B. -2006.-V.7.-P. 436−444.
120. Lichtenberg D, Barenholz Y. Liposomes: preparation, characterization, and preservation. // Methods Biochem Anal. 1988. — V. 33. — P. 337−462.
121. Litzinger DC, Huang L. Phosphatidylethanolamine liposomes: drug delivery, gene transfer and immunodiagnostic applications. // Biochim Biophys Acta. — 1992.-V. 1113.-P. 201−227.
122. Liu T, Zhang YZ, Wu XF. High level expression of functionally active human lactoferrin in silkworm larvae. // J. Biotechnol. 2005. — V. 118. — P. 246−256.
123. Liu T, Zhang YZ, Wu XF. Recombinant functional human lactoferrin expressed in baculovims system. // Acta Biochim. Biophys. Sin. (Shanghai).- 2006. — V.38.-P. 201−206.
124. Logan, J., Shenk, T. Adenovirus tripartite leader sequence enhances translation of mRNAs late after infection. // Proc. Natl. Acad. Sci. USA.- 1984. V.81. -P. 3655−3659.
125. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagenW/ J. Biol. Chem. 1951. — V. 193. — P. 265−275.
126. Maaks S., Yan H. Z. and Wood W. G. Development and evaluation of luminescence based sandwich assay for plasma lactoferrin as a marker for sepsis and bacterial infections in pediatric medicine. J. // Biolumines. Chemilumines. -1989.-V. 3.-P. 221−226.
127. Mancini LO, J. Anderson, V. Jasty, V.J. Yates. Tumor induction in hamster inoculated with an avian adenovirus (CELO). Arch. Gesamte Virusforsch. -1970.- V. 30.-P.261−262.
128. Maneva AI, Sirakov LM, Manev VV. Lactoferrin binding to neutrophilic polymorphonuclear leucocytes. // Int J Biochem. 1983. — V. 15. — P. 981−984.
129. Mann DM, Romm E, Migliorini M. Delineation of the glycosaminoglycan-binding site in the human inflammatory response protein lactoferrin. // J Biol Chem. 1994. — V. 269.-P. 23 661−23 667.
130. Marchetti M, Longhi C, Conte MP, Pisani S, Valenti P, Seganti L. Lactoferrin inhibits herpes simplex virus type 1 adsorption to Vero cells. // Antiviral Res. — 1996.-V. 29.-P. 221−231.
131. Markert JM, Gillespie GY, Weichselbaum RR, Roizman B, Whitley RJ. ' Genetically engineered HSV in the treatment of glioma: a review. // Rev Med Virol. 2000. — V. 10. — P. 17−30.
132. Matthews DA, Russell WC. Adenovirus protein-protein interactions: molecular parameters governing the binding of protein VI to hexon and the activation of the adenovirus 23K protease. // J Gen Virol. 1995. — V. 76. — P. 1959−69.
133. Mattsby-Baltzer I, Roseanu A, Motas C, Elverfors J, Engberg I, Hanson LA. Lactoferrin or a fragment thereof inhibits the endotoxin-induced interleukin-6 response in human monocytic cells. // Pediatr Res. 1996. — V. 40. — P. 257−62.
134. Medin JA, Fowler DH. Post-transduction events in retrovirus-mediated gene therapy involving hematopoietic stem cells: beyond efficiency issues. // J Cell Biochem Suppl. 2002. — V. 38. — P. 46−54.
135. Michael SI, Hong JS, Curiel DT, Engler JA. Addition of a short peptide ligand to the adenovirus fiber protein. // Gene Ther. 1995. — V. 2, N 9. — P. 660−668.
136. Michou A-I. et al. Mutational analysis of the avian adenovirus CELO, which provides a basis for gene delivery vectors. // J. Virol. 1999. — V. 73. — P. 1399−1410.
137. Mincheva-Nilsson L, Hammarstrom S, Hammarstrom ML. Activated human gamma delta T lymphocytes express functional lactoferrin receptors. // Scand J Immunol. 1997.-V. 46.-P. 609−618.
138. Mittereder N, March KL, Trapnell ВС. Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy. // J Virol. — 1996. — V. 70. — P. 7498−7509.
139. Miyazawa N, Leopold PL, Hackett NR, Ferris B, Worgall S, Falck-Pedersen E, Crystal RG. Fiber swap between adenovirus subgroups В and С alters intracellular trafficking of adenovirus gene transfer vectors. // J. Virol. 1999. -V. 73.-P. 6056−6065.
140. Motoi F, Sunamura M, Ding L, Duda DG, Yoshida Y, Zhang W, Matsuno S, Hamada H. Effective gene therapy for pancreatic cancer by cytokines mediatedby restricted replication-competent adenovirus. // Hum Gene Ther. 2000. — V. 11.-P. 223−235.
141. Na YJ, Han SB, Kang JS, Yoon YD, Park SK, Kim HM, Yang KH, Joe CO. Lactoferrin works as a new LPS-binding protein in inflammatory activation of macrophages. // Int Immunopharmacol. 2004. — V. 4. — P. 1187−1199.
142. Nakane PK., Kawaio A.S. Peroxidase-labeled antibody. A new method of conjugation. // J Histochem Cytochem. 1974. — V. 22. — P. 1084−1091
143. Nguyen JT, Wu P, Clouse ME, Hlatky L, Terwilliger EF. Adeno-associated virus-mediated delivery of antiangiogenic factors as an antitumor strategy. // Cancer Res. 1998. — V. 58. — P. 5673−5677.
144. Noureddini SC, Curiel DT. Genetic targeting strategies for adenovirus. // Mol. Pharm. 2005. — V. 2. — P. 341−347.
145. Ono M, Okuda Y, Yazawa S, Shibata I, Tanimura N, Kimura K, Haritani M, Mase M, Sato S Epizootic outbreaks of gizzard erosion associated with adenovirus infection in chickens. // Avian Dis. — 2001. V. 45. — P. 268−275.
146. Orsi N. The antimicrobial activity of lactoferrin: current status and perspectives. //Biometals. 2004. — V. 17.-P. 189−196.
147. Ott VD, Diukareva SV, Melnikov OR. Lactoferrin and perspectives for dietary prevention of anemia. // Vopr Pitan. 1993. — N 1. — P. 6−13.
148. Pay et V, Arnauld C, Picault JP, Jestin A, Langlois P / Transcriptional organization of the avian adenovirus CELO.// J Virol. 1998. — V. 72. — P. 92 789 285.
149. Plaut AG, Qiu J, St Geme JW 3rd. Human lactoferrin proteolytic activity: analysis of the cleaved region in the IgA protease of Haemophilus influenzae. // Vaccine. -2000. V. 19.-P. 148−152.
150. Poeschla EM, Wong-Staal F, Looney DJ. Efficient transduction of nondividing human cells by feline immunodeficiency virus lentiviral vectors. // Nat Med. -1998.-V. 4.-P. 354−357. •
151. Qiu J, Hendrixson DR, Baker EN, Murphy TF, St Geme JW 3rd, Plaut AG. Human milk lactoferrin inactivates two putative colonization factors expressed, , by Haemophilus influenzae. // Proc Natl Acad Sci USA.- 1998. V. 95. — P. ««» 12 641−12 646.t
152. Rainard P. Bacteriostatic activity of bovine milk lactoferrin against mastitic bacteria. // Vet Microbiol. 1986. — V. 11. — P. 387−392.
153. Reghunathan R, Jayapal M, Hsu LY, Chng HH, Tai D, Leung BP, Melendez AJ. Expression profile of immune response genes in patients with Severe Acute Respiratory Syndrome. // BMC Immunol. 2005. — V. 6. — P. 2.
154. Rekosh DM, Russell WC, Bellet AJ, Robinson AJ. Identification of a protein linked to the ends of adenovirus DNA. // Cell. 1977. — V. 11. — P. 283−295.
155. Riley, D., Flint, S.J. RNA-binding properties of a translational activator, the adenovirus L4 100-kilodalton protein. // J. Virol. 1993. — V.67. — P. 3586−3595.
156. Romanczuk H, Galer CE, Zabner J, Barsomian G, Wads worth SC, O’Riordan CR. Modification of an adenoviral vector with biologically selected peptides: a novel strategy for gene delivery to cells of choice. // Hum. Gene Ther. 1999. -V. 10.-P. 2615−2626.
157. Romano G, Pacilio C, Giordano A. Gene transfer technology in therapy: current applications and future goals. // Stem Cells. 1999. — V. 17. — P. 191−202.
158. Rowe W.P., Huebner R.J., Gilmor L.K., Parrott R.H., Ward T.G. Isolation of a cytopathogenic agent from human adenoids undergoigs spontaneous degeneration in tissue culture. // Proc. Soc. Exp. Biol. Med. 1953. — V. 84. — P. 570−573.
159. Schiaffino MV, Dellambra E, Cortese K, Baschirotto C, Bondanza S, Clementi M, Nucci P, Ballabio A, Tacchetti C, De Luca M. Effective retrovirus-mediated gene transfer in normal and mutant human melanocytes. // Hum Gene Ther. -2002.-V. 13.-P. 947−957.
160. Schneider RJ. Cap-independent translation in adenovirus infected cells. // Curr. Top. Microbiol. Immunol. 1995.-V. 203.-P. 117−129.
161. Shashkova EV, Cherenova LV, Kazansky DB, Doronin K. Avian adenovirus vector CELO-TK displays anticancer activity in human cancer cells and suppresses established murine melanoma tumors. // Cancer Gene Ther. 2005. — V. 12.-P. 617−626.
162. Shayakhmetov D.M., Papayannopoulou Т., Stamatoyannopoulos G., Lieber A. Efficient gene transfer into human CD34(+) cells by a retargeted adenovirus vector. // J. Virol. -2000. V. 74. — P. 2567−2583.
163. Sheay W, Nelson S, Martinez I, Chu TH, Bhatia S, Dornburg R. Downstream insertion of the adenovirus tripartite leader sequence enhances expression in universal eukaryotic vectors. // Biotechniques. 1993. — V. 15. — P. 856−862.
164. Shenk T. Adenoviridae: The viruses and their replication. Philadelphia. 1996. -Raven Publisher. — P. 2115−2119.
165. Shenk T, Williams J. Genetic analysis of adenoviruses. // Curr Top Microbiol Immunol.-1984.-V. 111.-P. 1−39.
166. Sheppard M, Werner W, Tsatas E, McCoy R, Prowse S, Johnson M. Fowl adenovirus recombinant expressing VP2 of infectious bursal disease virus induces protective immunity against bursal disease. // Arch. Virol. — 1998. V. 143.-P. 915−930.
167. Shiau AL, Lin PR, Chang MY, Wu CL. Retro virus-mediated transfer of prothymosin gene inhibits tumor growth and prolongs survival in murine bladder cancer. // Gene Ther. -2001. V. 8.-P. 1609−1617.
168. Shimamura M, Yamamoto Y, Ashino H, Oikawa T, Hazato T, Tsuda H, Iigo M. Bovine lactoferrin inhibits tumor-induced angiogenesis. // Int J Cancer. 2004. -V. 111.-P. 111−116.
169. Siebert PD, Huang ВС. Identification of an alternative form of human lactoferrin mRNA that is expressed differentially in normal tissues and tumor-derived cell lines. // Proc Natl Acad Sci USA.- 1997. V. 94. — P. 2198−2203.
170. Singh PK, Parsek MR, Greenberg EP, Welsh MJ. A component of innate immunity prevents bacterial biofilm development. // Nature. 2002. — V. 417. -P. 552−555.
171. Sorimachi K., Akimoto K., Hattori Y., Leiri T. and Niwa A. Activation of macrophages by lactoferrin: secretion of TNF-a, IL-8 and NO. // Biochem. Mol. Biol. Int. 1997. — V. 43. — P. 79−87.
172. Stewart PL, Fuller SD, Burnett RM. Difference imaging of adenovirus: bridging the resolution gap between X-ray crystallography and electron microscopy. // EMBO J. 1993. — V. 12. — P. 2589−2599.
173. Stowell KM, Rado ТА, Funk WD, Tweedie JW. Expression of cloned human lactoferrin in baby-hamster kidney cells. // Biochem J. 1991. — V. 276. — P. 349−355.
174. Suzuki YA, Lonnerdal B. Characterization of mammalian receptors for lactoferrin. // Biochem Cell Biol. 2002. — V. 80. — P. 75−80.
175. Takakura N, Wakabayashi H, Ishibashi H, Yamauchi K, Teraguchi S, Tamura Y, Yamaguchi H, Abe S. Effect of orally administered bovine lactoferrin on the immune response in the oral candidiasis murine model. // J Med Microbiol. — 2004.-V. 53.-P. 495−500.
176. Tan PK, Michou AI, Bergelson JM, Cotten M. Defining CAR as a cellular receptor for the avian adenovirus CELO using a genetic analysis of the two viral fibre proteins. // J Gen Virol. 2001. — V. 82. — P. 1465−1472.
177. Tani F, Iio K, Chiba H, Yoshikawa M. Isolation and characterization of opioid antagonist peptides derived from human lactoferrin. // Agric Biol Chem. 1990. -V. 54.1-P. 1803−1810.
178. Tartaglia J, Bonnet MC, Berinstein N, Barber B, Klein M, Moingeon P. Therapeutic vaccines against melanoma and colorectal cancer. // Vaccine. -2001.-V. 19.-P. 2571−2575.
179. Valenti P, Antonini G. Lactoferrin: an important host defence against microbial and viral attack. // Cell Mol. Life Sci. 2005. — V. 62. — P. 2576−2587.
180. Van Berkel РН, van Veen HA, Geerts ME, de Boer HA, Nuijens JH. Heterogeneity in utilization of N-glycosylation sites Asn624 and Asnl38 in human lactoferrin: a study with glycosylation-site mutants. // Biochem J. 1996. -V. 319.-P. 117−122.
181. Van der Eb A.J., van Kesteren J.W., van Bruggen E.F.J. Structural properties of adenovirus DNAs. II Biochem. Biophys. Acta. 1969. — V. 182. — P. 530 541.
182. Van Hooijdonk AC, Kussendrager KD, Steijns JM. In vivo antimicrobial and antiviral activity of components in bovine milk and colostrum involved in nonspecific defence. // Br J Nutr. 2000. — V. 84. — P. 127−134.
183. Vile R.G. A marriage of viral vectors. // Nature Biotech. -1997. -V. 15. P. ^ 840−841.
184. Volpers C, Kochanek S. Adenoviral vectors for gene transfer and therapy. // J. Gene Med. -2004. V. 6.-P. 164−171.
185. Vorland LH. Lactoferrin: a multifunctional glycoprotein. // APMIS. 1999. — V. 107.-P. 971−981.
186. Wakabayashi H., Takase M. and Tomita M. Lactoferricin derived from milk protein lactoferrin. // Curr. Pharm. Des. 2003. — V. 9. — P. 1277−1287.
187. Wang G, Williams G, Xia H, Hickey M, Shao J, Davidson BL, McCray PB. Apical barriers to airway epithelial cell gene transfer with amphotropic retroviral vectors. // Gene Ther. 2002. — V. 9 — P. 922−931.
188. Wang Q, Greenburg G, Bunch D, Farson D, Finer MH. Persistent transgene expression in mouse liver following in vivo gene transfer with a delta El/delta E4 adenovirus vector. Gene Ther. 1997. -V. 4. — P. 393−400.
189. Ward PP, Lo JY, Duke M, May GS, Headon DR, Conneely OM. Production ofbiologically active recombinant human lactoferrin in Aspergillus oryzae. //I
190. Biotechnology (N Y). 1992. — V. 10. — P. 784−789.
191. Ward PP, May GS, Headon DR, Conneely OM. An inducible expression system for the production of human lactoferrin in Aspergillus nidulans. // Gene. 1992. -V. 122.-P. 219−223.
192. Ward PP, Piddington CS, Cunningham GA, Zhou X, Wyatt RD, Conneely OM. A system for production of commercial quantities of human lactoferrin: a broad spectrum natural antibiotic. // Biotechnology (N Y). 1995. — V. 13. — P. 498 503.
193. Ward PP, Uribe-Luna S, Conneely OM. Lactoferrin and host defense. // Biochem. Cell Biol. 2002. — V. 80. — P. 95−102.
194. Washietl S, Eisenhaber F. Reannotation of the CELO genome characterizes a set of previously unassigned open reading frames and points to novel modes of host interaction in avian adenoviruses. // BMC Bioinformatics. 2003. V. 4. — P. 55.
195. Weber J. Genetic analysis of adenovirus type 2 III. Temperature sensitivity of processing viral proteins. // J. Virol. 1976. — V. 17. — P. 462−471.
196. Webster A, Russell WC, Kemp GD. Characterization of the adenovirus proteinase: development and use of a specific peptide assay. // J Gen Virol. —-1989.-V. 70.-P. 3215−3223.
197. Wickham TJ. Targeting adenovirus. // Gene Ther. 2000. — V. 7. — P. 110−114.
198. Wickham TJ, Segal DM, Roelvink PW, Carrion ME, Lizonova A, Lee GM, Kovesdi I. Targeted adenovirus gene transfer to endothelial and smooth muscle cells by using bispecific antibodies. II J. Virol. 1996. — V. 70. — P. 6831−6838.
199. Williams AF, Barclay AN. The immunoglobulin superfamily—domains for cell surface recognition. // Annu Rev Immunol. 1988. — V. 6. — P. 381−405.
200. Wilson DR. Viral-mediated gene transfer for cancer treatment. // Curr. Pharm. Biotechnol. -2002. V. 3.-P. 151−164.
201. Windheim M, Burgert HG. Characterization of E3/49K, a novel, highlyglycosylated E3 protein of the epidemic keratoconjunctivitis-causing adenovirustype 19a.//J. Virol. -2002. V. 76.-P. 755−766.
202. Wu SC, Huang GY, Liu JH. Production of retrovirus and adenovirus vectors for gene therapy: a comparative study using microcarrier and stationary cell culture. // Biotechnol Prog. 2002. — V. 18. — P. 617−622.
203. Xi Q, Cuesta R, Schneider RJ. Regulation of translation by ribosome shunting through phosphotyrosine-dependent coupling of adenovirus protein 100k to viral mRNAs. //J Virol.-2005.-V. 79.-P. 5676−5683.
204. Xiao B, Li QW, Feng B, Han ZS, Gao da W, Li J, Li K, Zhao R, Jiang ZL, Hu JH, Zhi XB. High-level expression of recombinant human nerve growth factor beta in milk of nontransgenic rabbits. // J. Biosci. Bioeng. 2008. — V. 105. — P. 327−334.
205. Yates V.J., Fry D.E. Observations on a chicken embryo lethal orphan (CELO) virus. // Am. J. Vet. Res. 1957. — V. 18. — P. 657−660.
206. Young CS. The structure and function of the adenovirus major late promoter. // Curr Top Microbiol Immunol. 2003. — V. 272. — P. 213−249.
207. Yueh A, Schneider RJ. Translation by ribosome shunting on adenovirus and hsp70 mRNAs facilitated by complementarity to 18S rRNA. // Genes Dev. — 2000.-V. 14.-P. 414−421.
208. Zabner J, Chillon M, Grunst T, Moninger TO, Davidson BL, Gregory R, Armentano D. A chimeric type 2 adenovirus vector with a type 17 fiber enhances gene transfer to human airway epithelia. // Curr. Top. Microbiol. Immunol. 2003. — V. 272. — P. 213−249.
209. Zagulski T, Lipinski P, Zagulska A, Broniek S, Jarzabek Z. Lactoferrin can protect mice against a lethal dose of Escherichia coli in experimental infection in vivo. И Br J Exp Pathol. 1989. — V. 70. — P. 697−704.
210. Zhang GH, Mann DM, Tsai CM. Neutralization of endotoxin in vitro and in vivo by a human lactoferrin-derived peptide. // Infect Immun. 1999. — V. 67. — P. 1353−1358.
211. Zhang J, Li L, Cai Y, Xu X, Chen J, Wu Y, Yu H, Yu G, Liu S, Zhang A, Chen J, Cheng G. Expression of active recombinant human lactoferrin in the milk of transgenic goats. // Protein Expr. Purif. 2008. — V. 57. — P. 127−135.
212. Zimecki M, Kocieba M, Kruzel M. Immunoregulatory activities of lactoferrin in the delayed type hypersensitivity in mice are mediated by a receptor with affinity to mannose. //Immunobiology. 2002. — V. 205. — P. 120−131.
213. Zimecki M, Mazurier J, Machnicki M, Wieczorek Z, Montreuil J, Spik G. Immunostimulatory activity of lactotransferrin and maturation of CD4- CD8-murine thymocytes. // Immunol Lett. 1991. — V. 30. — P. 119−123.
214. Zimecki M, Mazurier J, Spik G, Kapp JA. Human lactoferrin induces phenotypic and functional changes in murine splenic В cells. // Immunology. 1995. — V. 86.-P. 122−127.